Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
rhPTH · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| rhPTH(1-34) | DRUG | - |
| SB-751689 100 mg | DRUG | - |
| SB-751689 400 mg | DRUG | - |
Inclusion Criteria: * Healthy postmenopausal women 40 to 65 years of age, inclusive, meeting at least one of the following: Postmenopausal defined by the STRAW criteria of 12 months of spontaneous amenorrhea with serum FSH levels = 40 mIU/mL; History of bilateral oophorectomy (with or without hyste...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Precision BioSciences, Inc. | DTIL | 1 | N/A | Undisclosed |
| SI-BONE, Inc. | SIBN | 1 | - | Undisclosed |
rhPTH is an investigational small molecule being studied for the treatment of osteoporosis. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for its effects on calcium and phosphate excretion in postmenopausal women with osteoporosis.
rhPTH is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical trials to evaluate the safety and efficacy of rhPTH in patients with osteoporosis.
rhPTH is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved for commercial use. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing for osteoporosis.
rhPTH has been studied in one completed Phase 1 clinical trial with the identifier NCT00532077. The trial, titled 'A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women,' enrolled 40 female participants with osteoporosis in the United States.
rhPTH is also known as SB-751689, as indicated in the clinical trial title. The study evaluated the effects of both SB-751689 and rhPTH(1-34) on calcium and phosphate excretion in women with osteoporosis. These names may refer to the same investigational compound.